BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38191122)

  • 1. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
    Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
    Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer.
    Kato MK; Fujii E; Asami Y; Momozawa Y; Hiranuma K; Komatsu M; Hamamoto R; Ebata T; Matsumoto K; Ishikawa M; Kohno T; Kato T; Yoshida H; Shiraishi K
    Cancer Sci; 2024 May; 115(5):1646-1655. PubMed ID: 38433331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
    Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
    Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kaneko E; Sato N; Sugawara T; Noto A; Takahashi K; Makino K; Terada Y
    J Gynecol Oncol; 2021 Nov; 32(6):e79. PubMed ID: 34431253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.
    Post CCB; Stelloo E; Smit VTHBM; Ruano D; Tops CM; Vermij L; Rutten TA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Nout RA; Crosbie EJ; Powell ME; Mileshkin L; Leary A; Bessette P; Putter H; de Boer SM; Horeweg N; Nielsen M; Wezel TV; Bosse T; Creutzberg CL
    J Natl Cancer Inst; 2021 Sep; 113(9):1212-1220. PubMed ID: 33693762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 12. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.
    Haraldsdottir S; Hampel H; Tomsic J; Frankel WL; Pearlman R; de la Chapelle A; Pritchard CC
    Gastroenterology; 2014 Dec; 147(6):1308-1316.e1. PubMed ID: 25194673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
    Pasanen A; Loukovaara M; Bützow R
    Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation-specific Mismatch Repair-deficient Benign Endometrial Glands in Endometrial Biopsies and Curettings Are a Biomarker of Lynch Syndrome and Associate With Endometrial Carcinoma Development.
    Hegazy S; Brand RE; Dudley B; Karloski E; Lesnock JL; Elishaev E; Pai RK
    Am J Surg Pathol; 2023 Jul; 47(7):835-843. PubMed ID: 37226842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
    Hampel H; Pearlman R; de la Chapelle A; Pritchard CC; Zhao W; Jones D; Yilmaz A; Chen W; Frankel WL; Suarez AA; Cosgrove C; Backes F; Copeland L; Fowler J; O'Malley D; Salani R; McElroy JP; Stanich PP; Goodfellow P; Cohn DE
    Gynecol Oncol; 2021 Jan; 160(1):161-168. PubMed ID: 33393477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare germline mutation and MSH2-&MSH6 + expression in a double primary carcinoma of colorectal carcinoma and endometrial carcinoma: a case report.
    Zhang T; Huang X; Liu W; Ling X; Su Z; Huang M; Che S
    Diagn Pathol; 2024 Jan; 19(1):25. PubMed ID: 38297350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
    Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
    Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
    Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
    Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.